
Alessandra Vultaggio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6595037/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Hypersensitivity reactions to biologicals: An EAACI position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 39-54.	5.7	25
2	COVIDâ€19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals—EAACI recommendations. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2313-2336.	5.7	12
3	A Patient with Local Hypersensitivity Reactions to Three TNF-α Inhibitors and Local/Systemic Hypersensitivity Reactions to Tocilizumab: Desensitization to Tocilizumab. Journal of Ankara University Faculty of Medicine, 2022, 75, 130-133.	0.1	0
4	COVIDâ€19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 871-874.	5.7	33
5	Asthma and Chronic Rhinosinusitis: How Similar Are They in Pathogenesis and Treatment Responses?. International Journal of Molecular Sciences, 2021, 22, 3340.	4.1	27
6	Effect of dupilumab treatment in a severe asthma patient with EGPA. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3824-3825.	3.8	10
7	Strategies Targeting Type 2 Inflammation: From Monoclonal Antibodies to JAK-Inhibitors. Biomedicines, 2021, 9, 1497.	3.2	12
8	How to Prevent and Mitigate Hypersensitivity Reactions to Biologicals Induced by Anti-Drug Antibodies?. Frontiers in Immunology, 2021, 12, 765747.	4.8	8
9	Considerations on biologicals for patients with allergic disease in times of the COVIDâ€19 pandemic: An EAACI statement. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2764-2774.	5.7	75
10	Correlations Among Subcutaneous Immunoglobulin Dosage, ImmunoglobulinÂG Serum Pre-infusional Levels and Body Mass Index in Primary Antibody Deficiency Patients: A Pooled Analysis from the SHIFT/IBIS Studies. Clinical Drug Investigation, 2020, 40, 279-286.	2.2	3
11	COVID-19: general overview, pharmacological options and ventilatory support strategies. Multidisciplinary Respiratory Medicine, 2020, 15, 708.	1.5	2
12	Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With Polyangiitis. Allergy, Asthma and Immunology Research, 2020, 12, 885.	2.9	29
13	The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 2065-2072.e2.	3.8	18
14	Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question?. Respiratory Research, 2018, 19, 113.	3.6	139
15	The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review. Respiratory Research, 2018, 19, 154.	3.6	33
16	Biweekly Hizentra® in Primary Immunodeficiency: a Multicenter, Observational Cohort Study (IBIS). Journal of Clinical Immunology, 2018, 38, 602-609.	3.8	11
17	Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia. International Immunopharmacology, 2017, 44, 38-42.	3.8	13
18	Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies. International Journal of Immunopathology and Pharmacology, 2017, 30, 73-82.	2.1	21

#	Article	IF	CITATIONS
19	Hypersensitivity Reactions to Biologicals: True Allergy?. Current Treatment Options in Allergy, 2016, 3, 147-157.	2.2	4
20	Hypersensitivity Reactions to Biologic Agents. Immunology and Allergy Clinics of North America, 2014, 34, 615-632.	1.9	40
21	Assays and Strategies for Immunogenicity Assessment of Biological Agents. Drug Development Research, 2014, 75, S4-6.	2.9	19
22	Allergologicalin vitroandin vivoevaluation of patients with hypersensitivity reactions to infliximab. Clinical and Experimental Allergy, 2013, 43, n/a-n/a.	2.9	61
23	Drug-Specific Th2 Cells and IgE Antibodies in a Patient with Anaphylaxis to Rituximab. International Archives of Allergy and Immunology, 2012, 159, 321-326.	2.1	59
24	Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management. Current Opinion in Allergy and Clinical Immunology, 2011, 11, 262-268.	2.3	61
25	Acute infusion reactions induced by monoclonal antibody therapy. Expert Review of Clinical Immunology, 2011, 7, 55-63.	3.0	108